Toremifene and tamoxifen are equally effective for early-stage breast cancer: First results of International Breast Cancer Study Group trials 12-93 and 14-93

Annals of Oncology

Volumn 15, Issue 12, 2004, Pages 1749-1758

  Pagani, O ^a   Gelber, S ^b   Simoncini, E ^b   Castiglione Gertsch, M ^b   Price, K ^b   Zahrieh, D ^b   Gelber, R ^b   Coates, A ^b   Goldhirsch, A ^b  

^a Ospedale Beata Vergine   (Switzerland)

^b NONE

Author keywords

Adjuvant therapy; Early stage breast cancer; Tamoxifen; Toremifene

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; VAGINA BLEEDING; WEIGHT GAIN;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; RECEPTORS, ESTROGEN; TAMOXIFEN; TOREMIFENE; TREATMENT OUTCOME;

EID: 10944221233     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh463     Document Type: Article

References (55)

1. Ludwig Breast Cancer Study Group. Randomised trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984; 1: 1256-1260.
2. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive post-menopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-1394.
3. Rivkin SE, Green S, Metch B et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994; 12: 2078-2085.
4. Albain K, Green S, Osborne K et al. Tamoxifen (T) versus cyclophosphamide, Adriamycin® and 5-FU plus either con-current or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100). SWOG, ECOG, CALGB, NCCTG, and NCI-Canada. Proc ASCO 1997; 16: 128a.
5. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-1018.
6. Wils JA, Bliss JM, Marty M et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive post-menopausal patients with breast cancer: a randomised trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17: 1988-1998.
7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
8. Goldhirsch A, Wood WC, Gelber RD et al. Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 2003; 21: 3357-3365.
9. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 2002; 20: 3317-3327.
10. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
11. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
12. Kallio S, Kangas L, Blanco G et al. A new triphenylethylene compound, Fc-1157a. I Hormonal effects. Cancer Chemother Pharmacol 1986; 17: 103-108.
13. Kangas L, Nieminen AL, Blanco G et al. A new triphenylethylene compound, Fc-1157a. II Antitumor effects. Cancer Chemother Pharmacol 1986; 17: 109-113.
14. Shibutani S, Ravindernath A, Suzuki N et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000; 21: 1461-1467.
15. Li D, Dragan Y, Jordan VC et al. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 1997; 57: 1438-1441.
16. Hellmann-Blumberg U, Cartner MG, Wurz GT, DeGregorio MW. Intrinsic reactivity of tamoxifen and toremifene metabolites with DNA. Breast Cancer Res Treat 1998; 50: 135-141.
17. Williams GM, Ross PM, Jeffrey AM, Karlsson S. Genotoxicity studies with the antiestrogen toremifene. Drug Chem Toxicol 1998; 21: 449-476.
18. Shibutani S, Ravindernath A, Terashima I et al. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 2001; 61: 3925-3931.
19. Tomàs E, Kauppila A, Blanco G et al. Comparison between the effects of Tamoxifen and Toremifene on the uterus in postmenopausal breast cancer patients. Gynec Oncol 1995; 59: 261-266.
20. Marttunen MB, Cacciatore B, Hietanen P et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001; 84: 897-902.
21. Gershanovich M, Garin A, Baltina D et al. A Phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997; 45: 251-262.
22. Pukkala E, Kyyrönen P, Sankila R, Holli K. Tamoxifen and Toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer 2002; 100: 337-341.
23. Maenpaa J. Effects of the antiestrogens Tamoxifen, Toremifene and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1999; 91: 972.
24. Nayfield S, Gorin MB. Tamoxifen-associated eye disease: a review. J Clin Oncol 1996; 14: 1018-1026.
25. Parkkari M, Paakkala AM, Salminen L, Holli K. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand 2003; 81: 495-499.
26. Saarto T, Blomqvist C, Ehnholm C et al. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14: 429-433.
27. 8-cholestenol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995; 13: 2900-2905.
28. Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000; 63: 225-234.
29. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435-437.
30. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398-1406.
31. Fisher B, Costantino JP, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
32. Fisher B, Costantino JP, Wickerhan DL et al. Tamoxifen for the prevention of breast cancer: a report from the NSABP P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.
33. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-1467.
34. Pyrhonen S, Valavaara R, Modig H et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomised double-blind trial, the 'Nordic' phase III study. Br J Cancer 1997; 76: 270-277.
35. Hayes DE, Van Zyl JA, Hacking A et al. Randomised comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13: 2556-2566.
36. Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomised trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001; 65: 119-124.
37. Pyrhonen S, Ellmén J, Vuorinen J et al. Meta-analysis of trials comparing Toremifene with Tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56: 133-143.
38. Holli K, Valavaara R, Blanco G et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 2000; 18: 3487-3494.
39. Holli K. Tamoxifen versus Toremifene in the adjuvant treatment of breast cancer. Eur J Cancer 2002; 38: S37-S38.
40. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-410.
41. Sobin LH, Wittekind CH (eds). TNM classification of malignant tumors, 6th edition. New York, NY: Wiley-Liss 2002.
42. Davis BW, Zava DT, Locher GW et al. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984; 20: 375-382.
43. Berger U, Wilson P, McClelland RA et al. Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer. Hum Pathol 1987; 18: 1263-1267.
44. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-377.
45. Crivellari D, Bonetti M, Castiglione-Gertsch M et al for the International Breast Cancer Study Group. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18: 1412-1422.
46. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
47. Greenwood M. The natural duration of cancer. London, UK: Her Majesty's Stationary Office 1926; 1-26.
48. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
49. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc 1972; 34: 187-220.
50. Hürny C, Bernhard J, Coates A et al. for the International Breast Cancer Study Group. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 1996; 347: 1279-1284.
51. Bernhard J, Hürny C, Coates AS et al. for the International Breast Cancer Study Group. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. Ann Oncol 1997; 8: 825-835.
52. Ellmén J, Werner D, Hakulinen P et al. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. Cancer Chemother Pharmacol 2000; 45: 402-408.
53. Erkkola R, Nevala P, Mantyla E. Toremifene and breast cancer therapy: incidence of secondary endometrial cancers. Proc SABCS 2002; (Abstr 636).
54. Rochelle E, Curtis D, Freedman M et al. Risk of malignant mixed Mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96: 70-74.
55. Harvey HA, Hajba A. Stroke incidence with toremifene is lower than with tamoxifen in breast cancer patients. Proc Am Soc Clin Oncol 2003; 22: 741 (Abstr 2981).